Status: Not yet recruiting
SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response
This is an open-label, single-arm, multicenter clinical study to evaluate the efficacy and safety of SHR-A1811 in early or locally advanced HER2-positive breast cancer patients with suboptimal response to neoadjuvant regimen. Patients who were determined by the researchers to have poor therapeutic effect will switch to SHR-A1811.
Participants needed: 30
Trial details
Phase: Phase 2Age: 18-70Biological sex: FemaleType: InterventionalSponsor: Chuan WangUpdated: Aug 26, 2025
Eligibility criteria
1.Female patients with newly diagnosed breast cancer aged 18 to 70 years old; [+6]
1. Patients with metastatic or bilateral breast cancer, or inflammatory breast c... [+17]